Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.
2026 · 1st Quarter (Jan 1 - Mar 31)
CENTER FOR ADDICTION SCIENCE, POLICY, AND RESEARCH
Filed by TENAGRITY SOLUTIONS, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- TENAGRITY SOLUTIONS, LLC
- Filing UUID
- fb3c856e-64a5-4117-81a3-e643266b2d7a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.
Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.
Support for HR7840 (Event Contract Enforcement Act) addressing event contracts on war, etc. (recognizing such activity as gambling, a common addictive activity).
Literal federal measure citations: HR7840
Support for HR7840 (Event Contract Enforcement Act) addressing event contracts on war, etc. (recognizing such activity as gambling, a common addictive activity).
Literal federal measure citations: HR7840
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.